ACADIA Pharmaceuticals Inc (ACAD)
14.62
-0.19
(-1.28%)
USD |
NASDAQ |
Nov 04, 16:00
14.62
0.00 (0.00%)
After-Hours: 07:38
ACADIA Pharmaceuticals Revenue (Quarterly): 241.96M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 241.96M |
| March 31, 2024 | 205.83M |
| December 31, 2023 | 231.04M |
| September 30, 2023 | 211.70M |
| June 30, 2023 | 165.24M |
| March 31, 2023 | 118.46M |
| December 31, 2022 | 136.49M |
| September 30, 2022 | 130.71M |
| June 30, 2022 | 134.56M |
| March 31, 2022 | 115.47M |
| December 31, 2021 | 130.76M |
| September 30, 2021 | 131.61M |
| June 30, 2021 | 115.22M |
| March 31, 2021 | 106.55M |
| December 31, 2020 | 121.01M |
| September 30, 2020 | 120.58M |
| June 30, 2020 | 110.10M |
| March 31, 2020 | 90.07M |
| December 31, 2019 | 98.33M |
| September 30, 2019 | 94.59M |
| June 30, 2019 | 83.20M |
| March 31, 2019 | 62.96M |
| December 31, 2018 | 59.57M |
| September 30, 2018 | 58.30M |
| June 30, 2018 | 57.06M |
| Date | Value |
|---|---|
| March 31, 2018 | 48.87M |
| December 31, 2017 | 43.56M |
| September 30, 2017 | 35.58M |
| June 30, 2017 | 30.48M |
| March 31, 2017 | 15.29M |
| December 31, 2016 | 11.96M |
| September 30, 2016 | 5.268M |
| June 30, 2016 | 0.097M |
| March 31, 2016 | 0.004M |
| December 31, 2015 | 0.017M |
| September 30, 2015 | 0.039M |
| June 30, 2015 | 0.001M |
| March 31, 2015 | 0.004M |
| December 31, 2014 | 0.048M |
| September 30, 2014 | 0.015M |
| June 30, 2014 | 0.028M |
| March 31, 2014 | 0.03M |
| December 31, 2013 | 0.037M |
| September 30, 2013 | 0.24M |
| June 30, 2013 | 0.451M |
| March 31, 2013 | 0.417M |
| December 31, 2012 | 0.38M |
| September 30, 2012 | 3.478M |
| June 30, 2012 | 0.599M |
| March 31, 2012 | 0.45M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
90.07M
Minimum
Mar 2020
241.96M
Maximum
Jun 2024
142.93M
Average
130.71M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Biogen Inc | 2.466B |
| Madrigal Pharmaceuticals Inc | 62.18M |
| Supernus Pharmaceuticals Inc | 168.32M |
| Geovax Labs Inc | 0.3007M |
| Myomo Inc | 7.521M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 33.39M |
| Total Expenses (Quarterly) | 211.53M |
| EPS Diluted (Quarterly) | 0.20 |
| Enterprise Value | 1.924B |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | 13.80% |
| Earnings Yield | 1.23% |
| Operating Earnings Yield | 0.94% |
| Normalized Earnings Yield | 1.231 |